{"organizations": [], "uuid": "f0a37b20e187995ac98bb152a16f7a1033467773", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180427.html", "section_title": "Archive News &amp; Video for Friday, 27 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-pharma-mar-says-chugai-terminates/brief-pharma-mar-says-chugai-terminates-licensing-agreement-for-zepsyre-in-japan-idUSFWN1S41QC", "country": "US", "domain_rank": 408, "title": "BRIEF-Pharma Mar Says Chugai Terminates Licensing Agreement For Zepsyre In Japan", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.001, "site_type": "news", "published": "2018-04-28T00:12:00.000+03:00", "replies_count": 0, "uuid": "f0a37b20e187995ac98bb152a16f7a1033467773"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-pharma-mar-says-chugai-terminates/brief-pharma-mar-says-chugai-terminates-licensing-agreement-for-zepsyre-in-japan-idUSFWN1S41QC", "ord_in_thread": 0, "title": "BRIEF-Pharma Mar Says Chugai Terminates Licensing Agreement For Zepsyre In Japan", "locations": [], "entities": {"persons": [], "locations": [{"name": "japan", "sentiment": "none"}, {"name": "japan", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "chugai", "sentiment": "negative"}, {"name": "zepsyre", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 27 (Reuters) - Pharma Mar SA:\n* SAYS SUBMITS INFORMATION REGARDING THE TERMINATION OF THE LICENSING AGREEMENT FOR JAPAN ENTERED INTO WITH CHUGAI IN RELATION TO ZEPSYRE\n* EFFECTIVE DATE OF TERMINATION IS IN APRIL 2019 * TERMINATION DOES NOT AFFECT ANY PAYMENTS RECEIVED BY PHARMAMAR\n* TO INITIATE NEGOTIATIONS IN THE SHORT TERM WITH OTHER POTENTIAL LICENSEES FOR ZEPSYRE IN JAPAN\n* TO CONTINUE WITH PHASE I CLINICAL TRIALS INITIATED IN JAPAN IN 2017 FOR JAPANESE PATIENTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-28T00:12:00.000+03:00", "crawled": "2018-04-28T12:32:38.005+03:00", "highlightTitle": ""}